The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis

NCT ID: NCT00330135

Last Updated: 2008-01-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 85 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-01-31
• Study Completion Date: 2007-03-31

Brief Summary

To demonstrate the difference in terms of symptomatic efficacy between ADANT® sodium hyaluronate and placebo following an intra-articular injection in patients with symptomatic osteoarthritis of the hip.

Each patient will receive an injection of sodium hyaluronate or placebo in the symptomatic hip and will be followed up for three months.

At the third month, if the score for overall pain is still > 40 mm on the VAS, a second injection of ADANT® can be given irrespective of which treatment was received previously. The patient will be followed up for a further 3 months in an open-label fashion (monthly visits).

Conditions

Symptomatic Hip Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

Sodium hyaluronate 2.5 ml - 1 injection

Group Type: EXPERIMENTAL

Sodium hyaluronate

Intervention Type: DRUG

Sodium hyaluronate 2.5 ml - 1 injection

2

Placebo injection - 1 injection

Group Type: PLACEBO_COMPARATOR

placebo injection

Intervention Type: DRUG

placebo injection - 1 injection

Interventions

Sodium hyaluronate

Sodium hyaluronate 2.5 ml - 1 injection

Intervention Type: DRUG

placebo injection

placebo injection - 1 injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1. Primary osteoarthritis of the hip defined according to the ACR criteria; symptomatic, 2. Osteoarthritis of radiological grade II to III according to the Kellgren-Lawrence classification, using X-rays performed during the last three months, 3. Overall pain intensity between 40 and 80 mm on a VAS of 100 mm at the pre-screening examination, 4. The patients experienced pain at least one in two days during the last 30 days, it was resistant to paracetamol treatment at a dose of 4 g/day and a step 2 analgesic or a NSAID taken for at least 10 days, 5. A prosthesis is not planned in the next six months.

Exclusion Criteria

• Women who are pregnant or breastfeeding or women who could become pregnant and are not using effective contraception,
• Major dysplasia (defined using Lequesne's criteria as dislocation of the hip),
• Treatment by intra-articular injection of hyaluronic acid in the symptomatic hip during the 6 months prior to pre-screening,
• Patients with a history of hypersensitivity to any of the ingredients in the hyaluronan,
• The presence of inflammatory arthropathy or another disorder or condition that could affect the joint (e.g., rheumatoid arthritis, metabolic bone disease, femoral head necrosis, psoriasis, gout, infection),
• Another muscular or skeletal condition that could interfere with the evaluation of the efficacy of the treatment on the hip in question (evaluation of pain or functional handicap),
• Systemic corticosteroid therapy or intra-articular injection of corticosteroids into the ipsilateral hip or knee within the last month,
• Intermittent claudication or vascular disease,
• Previous surgery on the hip in question,
• Septic arthritis at any site,
• Any surgical procedure, including arthroplasty or arthroscopy, to the hip during the six months prior to pre-screening or surgery scheduled during the trial,
• Any chronic skin condition that could affect the site of the injection,
• Use of the investigational treatment or material during the last three months,
• Oral or injectable anticoagulant treatment,
• Antiaggregant platelet treatment, particularly low-dose aspirin,
• Symptomatic chondrocalcinosis in the painful hip

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daiichi Sankyo

INDUSTRY

Sponsor Role: lead

Responsible Party

Daiichi Sankyo France

Principal Investigators

Xavier Chevalier, Professor

Role: PRINCIPAL_INVESTIGATOR

Head of the department of rheumatology Hopital Henri Mondor, Creteil, France

Locations

Rueil-Malmaison, , France

Countries

France

References

Richette P, Ravaud P, Conrozier T, Euller-Ziegler L, Mazieres B, Maugars Y, Mulleman D, Clerson P, Chevalier X. Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial. Arthritis Rheum. 2009 Mar;60(3):824-30. doi: 10.1002/art.24301.

Reference Type: DERIVED

PMID: 19248105 (View on PubMed)

Other Identifiers

ADA 2003-01

Identifier Type: -

Identifier Source: org_study_id